Pristinamycin

Pristinamycin

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

Pristinamycin
Category Antibiotics
Catalog number BBF-03963
CAS 270076-60-3
Molecular Weight 1392.55
Molecular Formula C73H89N11O17

Ordering Information

Catalog Number Size Price Stock Quantity
BBF-03963 10 mg $299 In stock
BBF-03963 100 mg $999 In stock

Online Inquiry

Add to cart

Description

Pristinamycin is a complex of antibiotics produced by streptomyces pristinaespiralis, containing two components Pristinamycin IA and Pristinamycin IIA. Pristinamycin IA is a macrolide, and Pristinamycin IIA (streptogramin A) is a depsipeptide. Pristinamycin has been indicated for the treatment of MRSA.

Specification

Synonyms Pyostacine; Stafac; Pristinamycine; Staphylomycin; Virginiamycin
Storage Store at -20°C
IUPAC Name N-(3-benzyl-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo[20.4.0.06,10]hexacosan-15-yl)-3-hydroxypyridine-2-carboxamide;(12Z,17Z,19Z)-21-hydroxy-11,19-dimethyl-10-propan-2-yl-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.03,7]octacosa-1(27),6,12,17,19,25(28)-hexaene-2,8,14,23-tetrone
Canonical SMILES CCC1C(=O)N2CCCC2C(=O)N(C(C(=O)N3CCC(=O)CC3C(=O)NC(C(=O)OC(C(C(=O)N1)NC(=O)C4=C(C=CC=N4)O)C)C5=CC=CC=C5)CC6=CC=CC=C6)C.CC1C=CC(=O)NCC=CC(=CC(CC(=O)CC2=NC(=CO2)C(=O)N3CCC=C3C(=O)OC1C(C)C)O)C
InChI InChI=1S/C43H49N7O10.C28H35N3O7/c1-4-29-40(56)49-21-12-17-30(49)41(57)48(3)32(23-26-13-7-5-8-14-26)42(58)50-22-19-28(51)24-31(50)37(53)47-35(27-15-9-6-10-16-27)43(59)60-25(2)34(38(54)45-29)46-39(55)36-33(52)18-11-20-44-36;1-17(2)26-19(4)9-10-24(34)29-11-5-7-18(3)13-20(32)14-21(33)15-25-30-22(16-37-25)27(35)31-12-6-8-23(31)28(36)38-26/h5-11,13-16,18,20,25,29-32,34-35,52H,4,12,17,19,21-24H2,1-3H3,(H,45,54)(H,46,55)(H,47,53);5,7-10,13,16-17,19-20,26,32H,6,11-12,14-15H2,1-4H3,(H,29,34)/b;7-5-,10-9-,18-13-
InChI Key MVTQIFVKRXBCHS-FHWPYUEJSA-N

Properties

Appearance Pale Yellow Solid
Melting Point >157°C (dec.)

Reference Reading

1. Functional investigation of AfsKRS regulatory system for pristinamycin biosynthesis in Streptomyces pristinaespiralis
Na Shen, Zhige Wu, Haipeng Liao, Yu Yang, Qingchao Jin, Yanping Dou, Zhihua Jin 3 Biotech . 2021 Sep;11(9):418. doi: 10.1007/s13205-021-02933-2.
Three genes encoding AfsK, AfsR, AfsS homologues inStreptomyces pristinaespiraliswere studied, respectively, to investigate regulatory role of AfsKRS system for pristinamycin biosynthesis. Transcription change and gene inactivation analysis indicated that these genes had active transcription and positive regulation for the improvement of pristinamycin production inS. pristinaespiralis. The analysis of AfsKRS-defective mutagenesis indicated that there might be a positive correlation between the product ofafsKand pristinamycin I biosynthesis, and a negative correlation to pristinamycin II biosynthesis. However, bothafsRandafsSmight have negative correlation to pristinamycin I production and positive correlation to pristinamycin II production. The effects on pristinamycin production of AfsKRS disruptants by protein kinase inhibitor K252a indicated that AfsR, both not AfsK and AfsS, was the inhibition target of K252a inS. pristinaespiralis, and AfsR should serve as a pleiotropic regulator to have differential regulation on biosynthesis of pristinamycin I and II components. Based on above study, it might be deduced that different signal transduction patterns via AfsK, AfsR, AfsS of AfsKRS system should be involved in respective regulation for biosynthesis of pristinamycin I and II inS. pristinaespiralis. In conclusion, the investigation could give some valuable clues for exploring furtherly regulatory function of AfsKRS system inS. pristinaespiralis.
2. Pristinamycin: old drug, new tricks?
Amanda Gwee, Nigel Curtis, Noel Cranswick, Eden C Cooper J Antimicrob Chemother . 2014 Sep;69(9):2319-25. doi: 10.1093/jac/dku167.
Osteoarticular infections with Gram positive bacteria present an increasing challenge in an era of multidrug-resistant organisms. Prolonged intravenous antibiotic treatment is often required, with associated risks, costs and difficulties with administration; a safe, effective oral option would be ideal for this indication. Pristinamycin, an oral streptogramin antibiotic with bactericidal activity against Gram positive organisms including methicillin-resistant Staphylococcus aureus, has been used for over 50 years in Europe for the treatment of osteoarticular infections. We review the published evidence for the treatment of native bone and prosthesis-related osteoarticular infections with pristinamycin.
3. Use of Pristinamycin for Macrolide-Resistant Mycoplasma genitalium Infection
Sepehr N Tabrizi, Jennifer A Danielewski, Suzanne M Garland, Christopher K Fairley, Catriona S Bradshaw, Jørgen S Jensen, Gerald L Murray, Karen Worthington, Eric P F Chow, Tim R H Read, Jenny Su, Mieken Grant Emerg Infect Dis . 2018 Feb;24(2):328-335. doi: 10.3201/eid2402.170902.
High levels of macrolide resistance and increasing fluoroquinolone resistance are found in Mycoplasma genitalium in many countries. We evaluated pristinamycin for macrolide-resistant M. genitalium in a sexual health center in Australia. Microbiologic cure was determined by M. genitalium-specific 16S PCR 14-90 days after treatment began. Of 114 persons treated with pristinamycin, infection was cured in 85 (75%). This percentage did not change when pristinamycin was given at daily doses of 2 g or 4 g or at 3 g combined with 200 mg doxycycline. In infections with higher pretreatment bacterial load, treatment was twice as likely to fail for each 1 log10increase in bacterial load. Gastrointestinal side effects occurred in 7% of patients. Pristinamycin at maximum oral dose, or combined with doxycycline, cured 75% of macrolide-resistant M. genitalium infections. Pristinamycin is well-tolerated and remains an option where fluoroquinolones have failed or cannot be used.

Recommended Products

BBF-03753 Baicalin Inquiry
BBF-01826 Deoxymannojirimycin Inquiry
BBF-03754 CASTANOSPERMINE Inquiry
BBF-05862 Epirubicin Inquiry
BBF-01825 Loganin Inquiry
BBF-02614 Nystatin Inquiry

Bio Calculators

Stock concentration: *
Desired final volume: *
Desired concentration: *

L

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O c22h30n40
g/mol
g

Recently viewed products

Online Inquiry

Verification code
cartIcon
Inquiry Basket